当前位置: 首页 >> 检索结果
141. Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme.
作者: Cesare Hassan.;Carlo Senore.;Franco Radaelli.;Giovanni De Pretis.;Romano Sassatelli.;Arrigo Arrigoni.;Gianpiero Manes.;Arnaldo Amato.;Andrea Anderloni.;Franco Armelao.;Alessandra Mondardini.;Cristiano Spada.;Barbara Omazzi.;Maurizio Cavina.;Gianni Miori.;Chiara Campanale.;Giuliana Sereni.;Nereo Segnan.;Alessandro Repici.
来源: Gut. 2017年66卷11期1949-1955页
Miss rate of polyps has been shown to be substantially lower with full-spectrum endoscopy (FUSE) compared with standard forward-viewing (SFV) colonoscopy in a tandem study at per polyp analysis. However, there is uncertainty on whether FUSE is also associated with a higher detection rate of colorectal neoplasia, especially advanced lesions, in per patient analysis.
142. Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.
作者: Matthieu Allez.;Brett E Skolnick.;Maria Wisniewska-Jarosinska.;Robert Petryka.;Rune Viig Overgaard.
来源: Gut. 2017年66卷11期1918-1925页
Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D (NKG2D) receptors, which are expressed by T cells and innate lymphoid cells, and may be linked to mucosal damage in Crohn's disease (CD).
143. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study.
作者: Jacqueline M Lankelma.;Duncan R Cranendonk.;Clara Belzer.;Alex F de Vos.;Willem M de Vos.;Tom van der Poll.;W Joost Wiersinga.
来源: Gut. 2017年66卷9期1623-1630页
The gut microbiota is essential for the development of the intestinal immune system. Animal models have suggested that the gut microbiota also acts as a major modulator of systemic innate immunity during sepsis. Microbiota disruption by broad-spectrum antibiotics could thus have adverse effects on cellular responsiveness towards invading pathogens. As such, the use of antibiotics may attribute to immunosuppression as seen in sepsis. We aimed to test whether disruption of the gut microbiota affects systemic innate immune responses during endotoxemia in healthy subjects.
144. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
作者: Ankit Bhardwaj.;Chandan Kumar Kedarisetty.;Chitranshu Vashishtha.;Ajeet Singh Bhadoria.;Ankur Jindal.;Guresh Kumar.;Ashok Choudhary.;S M Shasthry.;Rakhi Maiwall.;Manoj Kumar.;Vikram Bhatia.;Shiv Kumar Sarin.
来源: Gut. 2017年66卷10期1838-1843页
Carvedilol is effective in the primary prophylaxis for large oesophageal varices. We investigated its use in preventing progression of small to large oesophageal varices.
145. Comparing CT colonography and flexible sigmoidoscopy: a randomised trial within a population-based screening programme.
作者: Daniele Regge.;Gabriella Iussich.;Nereo Segnan.;Loredana Correale.;Cesare Hassan.;Arrigo Arrigoni.;Roberto Asnaghi.;Piero Bestagini.;Gianmarco Bulighin.;Maria Carla Cassinis.;Andrea Ederle.;Andrea Ferraris.;Giovanni Galatola.;Teresa Gallo.;Giovanni Gandini.;Licia Garretti.;Maria Cristina Martina.;Daniela Molinar.;Stefania Montemezzi.;Lia Morra.;Massimiliano Motton.;Pietro Occhipinti.;Lucia Pinali.;Gian Alberto Soardi.;Carlo Senore.
来源: Gut. 2017年66卷8期1434-1440页
The role of CT colonography (CTC) as a colorectal cancer (CRC) screening test is uncertain. The aim of our trial was to compare participation and detection rate (DR) with sigmoidoscopy (flexible sigmoidoscopy (FS)) and CTC in a screening setting.
146. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
作者: J Tack.;K Schumacher.;G Tonini.;S Scartoni.;A Capriati.;C A Maggi.; .
来源: Gut. 2017年66卷8期1403-1413页
Tachykinins have been implicated in the pathophysiology of IBS with diarrhoea (IBS-D). Our aim was to study the efficacy and safety of ibodutant, a selective neurokinin-2 (NK2) receptor antagonist, in patients with IBS-D.
147. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial.
作者: Keith McIntosh.;David E Reed.;Theresa Schneider.;Frances Dang.;Ammar H Keshteli.;Giada De Palma.;Karen Madsen.;Premysl Bercik.;Stephen Vanner.
来源: Gut. 2017年66卷7期1241-1251页
To gain mechanistic insights, we compared effects of low fermentable oligosaccharides, disaccharides and monosaccharides and polyols (FODMAP) and high FODMAP diets on symptoms, the metabolome and the microbiome of patients with IBS.
148. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
作者: Kazunari Murakami.;Yuuichi Sakurai.;Madoka Shiino.;Nobuo Funao.;Akira Nishimura.;Masahiro Asaka.
来源: Gut. 2016年65卷9期1439-46页
The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy.
149. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
作者: Thomas Lee.;Thomas Clavel.;Kirill Smirnov.;Annemarie Schmidt.;Ilias Lagkouvardos.;Alesia Walker.;Marianna Lucio.;Bernhard Michalke.;Philippe Schmitt-Kopplin.;Richard Fedorak.;Dirk Haller.
来源: Gut. 2017年66卷5期863-871页
Iron deficiency is a common complication in patients with IBD and oral iron therapy is suggested to exacerbate IBD symptoms. We performed an open-labelled clinical trial to compare the effects of per oral (PO) versus intravenous (IV) iron replacement therapy (IRT).
150. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia.
作者: Grischa Terheggen.;Eva Maria Horn.;Michael Vieth.;Helmut Gabbert.;Markus Enderle.;Alexander Neugebauer.;Brigitte Schumacher.;Horst Neuhaus.
来源: Gut. 2017年66卷5期783-793页
For endoscopic resection of early GI neoplasia, endoscopic submucosal dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal resection (EMR). However, ESD is technically more difficult and evidence from randomised trial is missing.
151. Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial.
作者: S C van Doorn.;M van der Vlugt.;Actm Depla.;C A Wientjes.;R C Mallant-Hent.;P D Siersema.;Kmaj Tytgat.;H Tuynman.;S D Kuiken.;Gmp Houben.;Pcf Stokkers.;Lmg Moons.;Pmm Bossuyt.;P Fockens.;M W Mundt.;E Dekker.
来源: Gut. 2017年66卷3期438-445页
Colonoscopy is the current reference standard for the detection of colorectal neoplasia, but nevertheless adenomas remain undetected. The Endocuff, an endoscopic cap with plastic projections, may improve colonic visualisation and adenoma detection. The aim of this study was to compare the mean number of adenomas per patient (MAP) and the adenoma detection rate (ADR) between Endocuff-assisted colonoscopy (EAC) and conventional colonoscopy (CC).
152. Split-dose preparation for colonoscopy increases adenoma detection rate: a randomised controlled trial in an organised screening programme.
作者: F Radaelli.;S Paggi.;C Hassan.;C Senore.;R Fasoli.;A Anderloni.;F Buffoli.;M F Savarese.;G Spinzi.;D K Rex.;A Repici.
来源: Gut. 2017年66卷2期270-277页
Although a split regimen of bowel preparation has been associated with higher levels of bowel cleansing, it is still uncertain whether it has a favourable effect on the adenoma detection rate (ADR). The present study was aimed at evaluating whether a split regimen was superior to the traditional 'full-dose, day-before' regimen in terms of ADR.
153. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery.
作者: S Mondot.;P Lepage.;P Seksik.;M Allez.;X Tréton.;Y Bouhnik.;J F Colombel.;M Leclerc.;P Pochart.;J Doré.;P Marteau.; .
来源: Gut. 2016年65卷6期954-62页
Preventing postoperative recurrence after ileocolonic resection (ICR) for Crohn's disease (CD) is challenging. Defining the disturbances of the microbial composition and community structure after ICR and their link with early disease recurrence is crucial.
154. Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.
作者: An Moonen.;Vito Annese.;Ann Belmans.;Albert J Bredenoord.;Stanislas Bruley des Varannes.;Mario Costantini.;Bertrand Dousset.;J I Elizalde.;Uberto Fumagalli.;Marianne Gaudric.;Antonio Merla.;Andre J Smout.;Jan Tack.;Giovanni Zaninotto.;Olivier R Busch.;Guy E Boeckxstaens.
来源: Gut. 2016年65卷5期732-9页
Achalasia is a chronic motility disorder of the oesophagus for which laparoscopic Heller myotomy (LHM) and endoscopic pneumodilation (PD) are the most commonly used treatments. However, prospective data comparing their long-term efficacy is lacking.
155. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease.
作者: Aranzazu Jauregui-Amezaga.;Montserrat Rovira.;Pedro Marín.;Azucena Salas.;Susana Pinó-Donnay.;Faust Feu.;J Ignasi Elizalde.;Francesc Fernández-Avilés.;Carmen Martínez.;Gonzalo Gutiérrez.;Laura Rosiñol.;Enric Carreras.;Alvaro Urbano.;Miguel Lozano.;Joan Cid.;María Suárez-Lledó.;Josep Mensa.;Jordi Rimola.;Sonia Rodríguez.;Mari Carme Masamunt.;Dolors Comas.;Irene Ruíz.;Anna Ramírez-Morros.;Marta Gallego.;Ingrid Ordás.;Julian Panés.;Elena Ricart.
来源: Gut. 2016年65卷9期1456-62页
To evaluate the feasibility and toxicity of autologous haematopoietic stem cell transplantation (HSCT) for the treatment of refractory Crohn's disease (CD).
156. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
作者: Hemant K Roy.;Vladimir Turzhitsky.;Ramesh Wali.;Andrew J Radosevich.;Borko Jovanovic.;Gary Della'Zanna.;Asad Umar.;David T Rubin.;Michael J Goldberg.;Laura Bianchi.;Mart De La Cruz.;Andrej Bogojevic.;Irene B Helenowski.;Luz Rodriguez.;Robert Chatterton.;Silvia Skripkauskas.;Katherine Page.;Christopher R Weber.;Xiaoke Huang.;Ellen Richmond.;Raymond C Bergan.;Vadim Backman.
来源: Gut. 2017年66卷2期285-292页
A major impediment to translating chemoprevention to clinical practice has been lack of intermediate biomarkers. We previously reported that rectal interrogation with low-coherence enhanced backscattering spectroscopy (LEBS) detected microarchitectural manifestations of field carcinogenesis. We now wanted to ascertain if reversion of two LEBS markers spectral slope (SPEC) and fractal dimension (FRAC) could serve as a marker for chemopreventive efficacy.
157. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.
作者: Jyh-Ming Liou.;Chieh-Chang Chen.;Chi-Yang Chang.;Mei-Jyh Chen.;Chien-Chuan Chen.;Yu-Jen Fang.;Ji-Yuh Lee.;Tsung-Hua Yang.;Jiing-Chyuan Luo.;Jeng-Yih Wu.;Tai-Cherng Liou.;Wen-Hsiung Chang.;Yao-Chun Hsu.;Cheng-Hao Tseng.;Chun-Chao Chang.;Ming-Jong Bair.;Tzeng-Ying Liu.;Chun-Fu Hsieh.;Feng-Yun Tsao.;Chia-Tung Shun.;Jaw-Town Lin.;Yi-Chia Lee.;Ming-Shiang Wu.; .
来源: Gut. 2016年65卷11期1784-1792页
Significant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy for 14 days (T14) in the first-line treatment of Helicobacter pylori. We aimed to compare the efficacy of S10 and T14 and assess the factors affecting their efficacies.
158. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
作者: Wei Zhang.;Qi Chen.;Xiao Liang.;Wenzhong Liu.;Shudong Xiao.;David Y Graham.;Hong Lu.
来源: Gut. 2015年64卷11期1715-20页
To evaluate the efficacy and tolerability of replacing tetracycline with amoxicillin in bismuth quadruple therapy.
159. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication.
作者: Kai-feng Pan.;Lian Zhang.;Markus Gerhard.;Jun-ling Ma.;Wei-dong Liu.;Kurt Ulm.;Jian-xi Wang.;Lei Zhang.;Yang Zhang.;Monther Bajbouj.;Lan-fu Zhang.;Ming Li.;Michael Vieth.;Rui-yong Liu.;Michael Quante.;Le-hua Wang.;Stepan Suchanek.;Tong Zhou.;Wei-xiang Guan.;Roland Schmid.;Meinhard Classen.;Wei-cheng You.
来源: Gut. 2016年65卷1期9-18页
To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China.
160. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.
作者: Reena Khanna.;Guangyong Zou.;Geert D'Haens.;Paul Rutgeerts.;J W D McDonald.;Marco Daperno.;Brian G Feagan.;William J Sandborn.;Elena Dubcenco.;Larry Stitt.;Margaret K Vandervoort.;Allan Donner.;Allison Luo.;Barrett G Levesque.
来源: Gut. 2016年65卷7期1119-25页
The Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to assess Crohn's disease (CD) activity; however, neither instrument has been fully validated. We assessed intra-rater and inter-rater reliability of these indices.
|